Researchers assessed whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis, osteoarthritis, and psoriatic arthritis.
MAXIMISE trial results demonstrate the safety and efficacy of secukinumab 300 mg and 150 mg treatment for axial disease in people with psoriatic arthritis.
Low cardiovascular fitness in late adolescence is associated with an increased risk for incident psoriasis and psoriatic arthritis.
Researchers determined the causal associations between genetically predicted TNF-α, IL-12p70, and IL-17 levels and risk for psoriatic arthritis.
For adults with psoriatic diseases, the likelihood of developing bone fractures is increased.
Researchers assessed the risk for osteoarthritis in patients with PsA compared with those with psoriasis and the general population.
Researchers compared the effect of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function.
Atul A. Deodhar, MD, provides an insight into the latest research on psoriatic arthritis presented at ACR Convergence 2020.
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
An overview of the risk for infections during targeted and biologic therapies in rheumatoid arthritis and psoriatic arthritis.